Primary endpoint met in TRANSCEND-CLL-004 trial of liso-cel in R/R CLL

Topline results obtained from TRANSCEND-CLL-004 (NCT03331198) show that the trial met its primary endpoint of complete response rate in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The results indicate that lisocabtagene maraleucel (liso-cel) may be a safe and efficacious treatment option for this patient population.¹

TRANSCEND-CLL-004 is a phase I/II, open-label, multicenter study to determine the efficacy and safety of liso-cel in adult patients with R/R CLL or small lymphocytic leukemia (SLL). The primary endpoint was complete response rate compared to historical control in patients with R/R CLL that was refractory to a Bruton’s tyrosine kinase (BTK) inhibitor and pretreated with a B-cell lymphoma 2 inhibitor. Additionally, no new safety signals were observed.